29 There are several potential advantages in using ropinirole prolonged release versus the immediate release formulation, especially during the more advanced stages of PD.
After taking placebo for 7 days, 161 patients were randomized into four possible permutations of formulation sequence: 1) immediate release – immediate release – prolonged release, 2) immediate release – prolonged release – prolonged release, 3) prolonged release – prolonged release – immediate release and 4) prolonged release – immediate release – immediate release.
29 The bioavailability of ropinirole prolonged release compared to the immediate release formulation is nearly 100%.
Several potential advantages of ropinirole prolonged release compared to the immediate release formulation include maintaining more consistent dopaminergic activity with steadier plasma levels, increased tolerability, greater compliance from a simpler once-daily dosing regimen and ease in dose titration.
The dose-normalized Cmax for ropinirole prolonged release is slightly lower than the immediate release formulation (0.92 ng/mL/mg vs 1.05 ng/mL/mg), most likely resulting from a more gradual approximation of peak dose.
In 2008, the FDA approved ropinirole prolonged release which is a once daily 24-hour formulation of the dopamine agonist, ropinirole.
Therefore, a formulation of chemoattractant (e.g., fMLF) for prolonged release not only acts as a useful tool to study the biology of neutrophils over long duration, but also holds promise for therapeutic applications, like cancer treatment.
As would be expected, from a once-daily 8 mg dose of ropinirole prolonged release, the median time to achieve maximum plasma concentration is longer than that of the immediate release formulation dosed as 2.5 mg three times daily (∼6 hours vs ∼2 hours).
The burst release was due to incorporation of Pluronics and the prolonged release up to 6 h was attributed to the mucoadhesives used in the formulation.
Furthermore, slower absorption and steadier plasma levels with ropinirole prolonged release are likely to increase tolerability by reducing adverse effects associated with the more marked peak and troughs of the immediate release formulation.
